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Pulmonary surfactant is a multimolecular complex lo-
cated at the air-water interface within the alveolus to
which a range of physical (surface-active propert i e s )
and immune functions has been assigned. This complex
consists of a surface-active lipid layer (consisting mainly
of phospholipids), and of an aqueous subphase. From
discrete surfactant sub-fractions one can isolate
strongly hydrophobic surfactant proteins B (SP-B) and C
(SP-C) as well as collectins SP-A and SP-D, which were
shown to have specific structural, metabolic, or immu-
ne properties. Inborn or acquired abnormalities of the
s u rfactant, qualitative or quantitative in nature, account
for a number of human diseases. Beside hyaline mem-
brane disease of the preterm neonate, a cluster of hered-
itary or acquired lung diseases has been characterized
by periodic acid-Schiff-positive material filling the alve-
oli. From this heterogeneous nosologic group, at least
two discrete entities presently emerge. The first is the
SP-B deficiency, in which an essentially proteinaceous
material is stored within the alveoli, and which repre-
sents an autosomal recessive Mendelian entity linked to
the S F T P B gene (MIM 1786640). The disease usually
generally entails neonatal respiratory distress with
rapid fatal outcome, although partial or transient defi-
ciencies have also been observed. The second is alveo-
lar proteinosis, characterized by the storage of a mixed
protein and lipid material, which constitutes a relatively
heterogeneous clinical and biological syndrome, espe-
cially with regard to age at onset (from the neonate
through to adulthood) as well as the severity of associ-
ated signs. Murine models, with a targeted mutation of
the gene encoding granulocyte macrophage colony-
stimulating factor (GM-CSF) (C s f g m) or the  subunit of
its receptor (I l 3 r b 1) support the hypothesis of an abnor-
mality of surfactant turnover in which the alveolar
macrophage is a key player. Apart from SP-B deficiency,
in which a near-consensus diagnostic chart can be de-
signed, the ascertainment of other abnormalities of sur-
factant metabolism is not straightforward. The disent-
anglement of this disease cluster is however essential
to propose specific therapeutic procedures: repeated
broncho-alveolar lavages, GM-CSF replacement, bone
marrow grafting or lung transplantation.
Key words: Surfactant, pulmonary; Pulmonary alveolar
proteinosis; SP-B protein deficiency; Hyaline mem-
brane disease; Respiratory distress.
Abbreviations: BAL, bronchoalveolar lavage (fluid);
CAP, congenital (pulmonary) alveolar proteinosis;
DPPC, dipalmitoylphosphatidylcholine; GM-CSF, gran-
ulocyte-macrophage colony-stimulating factor; HMD,
hyaline membrane disease; LDH, lactate dehydroge-
nase; MBL, mannose-binding lectin; PAP, pulmonary
alveolar proteinosis; PAS, periodic acid-Schiff; proSP-
C, SP-C precursor protein; SP, surfactant protein; TA,
tracheal aspirate.
Introduction
Problems related to air breathing occur at many levels,
first physical, because air breathing entails the control
of forces that tend to collapse the alveoli, maximally in
end-expiration, without compromising the efficiency of
gas exchange. These problems are also infective and
depurant in nature, because the approximately 17 kg of
air breathed daily are liable to contain a large diversity
of chemicals, allergens, and pathogens which may
cause toxic, inflammatory end infectious problems. The
evolution of surfactant systems and of the proteins as
specific and integral components shows how, despite
the large diversity of present-day pulmonary structures,
a single biological mechanism was selected very early
during evolution for adaptation to the fundamental
problems related to air breathing (1). Indeed, the im-
munohistochemical analysis of surfactant from lung-
fish (Neoceratodus forsteri, a species separated from
man by approximately 400 million years), based on the
utilization of antibodies specifically raised against hu-
man surfactant proteins A (SP-A) and C (SP-B), elicits a
labelling pattern similar to human surfactant. Any alter-
ation of this interface system, the cause of which may
be acquired and transient, or inborn, will cause funda-
mental, possibly life-threatening, problems.
Components, Structure and Functions of Surfactant:
a Lipid and Protein Complex
The main source for the study of surfactant and its
components is broncho-alveolar lavage fluid. The sur-
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factant affects the alveolar space, although its surface-
active properties may extend to the tracheo-bronchial
tree. The large body of analyzed material originates
from the alveoli, and its raw composition does not mir-
ror the actual heterogeneity of the different physiologic
phases. Such heterogeneity is elicited after the frac-
tionation of discrete subfractions using thin-layer chro-
matography or sucrose gradient. The surface active
properties, aimed at lowering the air-liquid interface
pressure such as surface tension, come mainly from
the phospholipids. These phospholipids are arranged
as a layer separated from the apex of the cells by a thin
liquid film.
This is no static organization, since the lipid layer un-
dergoes condensation and spreading at each respira-
tory cycle. It has been estimated that surfactant lowers
the surface tension at the pulmonary air-water interface
approximately 70-fold. The absence, or malfunction, of
this lipid layer will lead to alveolar collapse, or atelecta-
sis, during expiration (2). Specific proteins (SP-A, SP-B,
SP-C, and SP-D) play an important part in the home-
ostasis of this component, at the levels of both struc-
tural organization and functional durability. Lung is not
only exposed to atmosphere gases, but also to physical,
toxic, infectious, and allergenic insults. This calls for as
many specific functions assigned to such proteins.
Lipids make up about 90% of the molar content of
pulmonary surfactant. They are mostly phospholipids
containing, in a decreasing order of magnitude, phos-
phatidylcholine, phosphatidylglycerol, phosphatidyleth-
anolamine, phosphatidylinositol, phosphatidylserine,
and sphingomyelins. Among phosphatidylcholines,
the dipalmitoylated compound is the most abundant
(dipalmitoylphosphatidylcholine: DPPC), accounting
for approximately 50% of these compounds. Finally,
cholesterol makes up approximately 8% of the weight
of lipids (15% mol), and there are only traces of triglyc-
erides or non-esterified fatty acids (3) (Table 1).
Proteins make approximately 10% of the molar con-
tent of surfactant. Four of them take up most of the
functions devoted to specific surfactant proteins.
These are two water-soluble proteins, SP-A and SP-D,
and two hydrophobic proteins, SP-B and SP-C (3)
(Table 2). SP-A and SP-D are collectins. This means that
they contain a collagen-like domain devoted to
oligomerization (N-terminal end), and a lectin-like do-
main allowing for the opsonization of xenobiotics and
pathogens (C-terminal end). This sub-family also in-
cludes mannose-binding protein (MBL2: mannose-
binding lectin) (10) (Figures 1, 2). SP-A is essential, in
conjunction with SP-B and ionized calcium, for the
scaffolding of tubular myelin, a transitional structure
between intracellular and alveolar surfactant. In addi-
tion, SP-A regulates the insertion of phospholipids into
the lipid layer at the air-liquid interface, modulates the
secretion and re-uptake of phospholipids by type II
Tab. 1 Phospholipid content (%) of pulmonary surfactant.1
Phospholipids Term-born neonates Preterm neonates SP-B deficient neonates
Phosphatidylcholine 80 70 75
DPPC (% of PC) 70 60 55
Phosphatidylglycerol 10 0 2
Phosphatidylethanolamine 3 5 7
Phosphatidylinositol 5 10 4
Phosphatidylserine 2 2 2
Sphingomyelin 2 15 8
phatidylcholine; PC: phosphatidylcholine.1 The pulmo ary surfactant components are indicated for
each phospholipid and for each pathophysiological condition
as percentages of total phospholipids (for DPPC, percent-
age in relation to phosphatidylcholines) (4). DPPC: dipalmi-
toylphosphatidylcholine; PC: phosphatidylcholine
Tab. 2 Surfactant proteins.1
Protein SP-A SP-D SP-B SP-C
Type Water-soluble Water-soluble Hydrophobic Hydrophobic
MW of the monomer 26–38 kDa 43 kDa 8.7 kDa 4.2 kDa
Quaternary structure Octodecamer (trimer hexamer) Dodecamer (trimer tetramer) Dimer Monomer
Receptors (MW) Calreticulin (∼60 kDa) gp-340 (340 kDa)
C1qRp (126 kDa)
SP-A receptor (210 kDa)
SP-A receptor (>200 kDa)
References (3, 5–8) (3, 8, 9) (3) (3)
1 for the corresponding genes, see Table 3. MW: molecular weight.
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alveolar cells in vitro, activates alveolar macrophages
(generation of free radicals), and opsonizes endotoxins
and some bacterial capsules (C1q-like function), and
aggregates pathogens (Hæmophilus influenzæ type
A). SP-A, together with SP-D, is an important element
of the non-specific immunity of the pulmonary mucosa
(11). SP-D, beside its role in the non-specific activation
of macrophages, interferes with phospholipid metabo-
lism. It binds phosphatidylinositol via calcium (3).
Some studies have elicited the antiallergenic action of
SP-A and SP-D. Indeed, SP-A and SP-D have the capac-
ity to inhibit the release of histamine by basophils fol-
lowing induction by an allergen (e.g., the fungal glyco-
protein of Aspergillus fumigatus) (12). In addition,
these proteins inhibit lymphocytic proliferation and
histamine release in asthmatic children (13). SP-A and
SP-D act as opsonins by means of membrane-bound
receptors (8). The best characterized receptor of SP-A is
a 210-kDa protein found at the surface of macrophages
and type II alveolar cells (14). Additional receptors have
Fig. 1 Primary structure of SP-A and SP-D proteins. Struc-
tural homology with the MBL protein is indicated from left to
right as follows: light grey, signal peptide; black, cysteine-rich
domain; medium grey, collagen-like domain; white, coiled-
coil domain; dark grey, type-C lectin domain. Disulfide bonds
are indicated for each protein in the lectin type-C domain, the
cysteine residues being represented by potential (open) disul-
fide bonds and the glycosylation sites by fork-like structures.
Fig. 2 Quaternary structures of proteins SP-A and SP-D.
These proteins are made from the assembly of homodimers
(six for SP-A and four for SP-D), the globular extremity corre-
sponding to the lectin domain (C-terminus).
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been identified on the surface of other cells, especially
neutrophils (Table 2). Several studies showed the bind-
ing of SP-D to alveolar macrophages. A 340-kDa recep-
tor (gp-340) was recently isolated from broncho-alveo-
lar lavage fluid (9). Whereas it is generally believed that
the collagen-like domain of the two collectins SP-A and
MBL contains the receptor binding site, it is on the in-
termediate domain of protein SP-D that the gp-340
binding site was identified (9). Beside the water-soluble
proteins, two hydrophobic proteins are intertwined
with phospholipids in the air-water interface. These
proteins are SP-B and SP-C. SP-B is composed of 79
amino acids and has an apparent molecular weight of
8.7 kDa. Proteolytic cleavage generates the mature pro-
tein, with a functional arrangement as a homodimer.
SP-C is composed of 35 amino acids and has a molecu-
lar weight of 4.2 kDa. This protein is strongly hy-
drophobic, due to a long valine-rich tail and to palmi-
toylation on two cysteine residues (Figures 3, 4).
Overall, SP-B and SP-C’s main functions are to catalyze
the insertion of phospholipids at the lung air-water in-
terface, to provide the molecular scaffolding of the
phospholipid layer, and to stabilize tubular myelin (SP-
B together with SP-A).
Metabolism
Synthesis
The synthesis of surfactant phospholipids and proteins
takes place in the microsomal fraction of the type II alve-
olar cells. Surfactant components are synthesized
within the endoplasmic reticulum and translocated to
the Golgi apparatus before they are stored as lamellar
inclusions (intracellular pool). Once excreted by exocy-
tosis, the lamellar bodies unpack in the subphase to
generate tubular myelin (extracellular or alveolar pool),
highly ordered transitional structure and precursor of
the lipid layer at the air-water interface (3, 21) (Figure 5).
Recycling
Surfactant is continuously excreted and recycled. In-
deed, the type II alveolar cells re-uptake surfactant to
Fig. 3 Gene encoding the SP-B protein (SFTPB) and propep-
tide processing. The SFTPB gene is localized on the short arm
of chromosome 2, in position 2p12–p11.2 (15). It is a relatively
small gene spanning 9.5 kb and composed of 11 exons, only
the first ten being coding. The nucleotide sequence corre-
sponding to the mature peptide spans exons 6 and 7 (16). The
use of an alternative splice site in the beginning of exon 8 gen-
erates a 12-nucleotide shorter messenger. The possible rela-
tionship between this messenger and human disease are still
speculative. The 381 amino acid (aa)-long precursor (proSP-B),
having a molecular weight (MW) of 40 kDa, generated by the
co-translational cleavage of a 23-residue signal, is again sub-
jected to a two-step proteolytic processing yielding the 79-aa,
8.7-kDa, mature peptide. The first step consists in the cleavage
of the N-terminal domain, yielding a 26-kDa intermediate pep-
tide, and the second ends with the cleavage of the C-terminal
domain and yielding of the mature peptide (17). The latter step
is restricted to the type II alveolar cells. The proteins involved
in the catalysis and post-translational processing of the proSP-
B precursor have not been identified to date.
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GM-CSF (Csfgm-/- mice) (22) or the subunit of its recep-
tor (Il3rb1-/- mice) (23) (see below).
Genes
As we have seen for SP-B and SP-C (Figures 3, 4),
most of the genes encoding surfactant-specific pro-
teins, or proteins involved in surfactant homeostasis,
have been localized and their intron-exon organization
is known (Table 3). These genes provide many candi-
dates for monogenic or polygenic factors determining
the diversity of primary or secondary disorders of pul-
monary surfactant metabolism. Indeed, mutations that
lead to inactivation of one of the genes involved in sur-
factant homeostasis, especially those encoding struc-
tural proteins, might, by abating or completely deplet-
ing the source of normal protein, cause respiratory
distress in a new-born, an infant, a child or an adult.
Such mutations could account for the observed recur-
rence in siblings, especially when they show a reces-
sive pattern of inheritance. On the other hand, slight
variation in coding or non-coding regions of these
genes might confer a certain risk related to lung dis-
ease, which might be primary (without any obvious
cause) or secondary to environmental insults. The
emerging molecular pathology of these genes in man,
or the corresponding murine models detailed below,
have in part corroborated this hypothesis (also, see
Table 4). Indeed, to investigate the involvement of dif-
ferent candidate genes in the mouse, or to establish
models for the human disease, several murine homo-
logues of human surfactant genes were knocked out
using homologous recombination. This concerns the
genes encoding the water-soluble proteins, SP-A
(Sftpa) and SP-D (Sftpd), the gene encoding hy-
drophobic SP-B (Sftpb), as well as the genes encoding
GM-CSF (Csfgm) or the β subunit of its receptor
(Il3rb1).
Disease Conditions
HMD
A number of respiratory diseases linked to an abnor-
mality of pulmonary surfactant have been described,
with a special mention of hyaline membrane disease of
the preterm neonate (HMD) (32). HMD is a common
cause for respiratory distress in the newborn and is re-
lated to an immaturity of the production and secretion
of pulmonary surfactant. Incidence is estimated at 1%
of births in the United States and is inversely propor-
tional to the gestational age and birth weight (33). The
absence of an efficient surfactant accounts for alveolar
collapse, the generation of hyaline membranes and in-
terstitial edema. Typically, the newborn child is man-
aged in a neonated intensive care unit, specific sup-
portive care resting on oxygen, sometimes early
administration of corticoids and assisted ventilation,
and finally the endotracheal instillation of replacement
recycle it via lamellar bodies (Figure 5). The control of
this process is poorly understood. An important frac-
tion of surfactant is recycled through type II alveolar
cells. Alveolar macrophages also have their share in
this process, although quantitatively for a lesser part,
by phagocytosis. Finally, a minute quantity of pul-
monary surfactant seems to be cleared by the airway. It
is of note that granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) and its downstream signaling
pathway are of importance in this process. Indeed, this
cytokine plays an outstanding role in macrophage acti-
vation and surfactant recycling, as shown by murine
models with a targeted mutation of the gene encoding
Fig. 4 Gene encoding the SP-C protein (SFTPC) and propep-
tide processing. The SFTPC gene is localized on the short arm
of chromosome 8, in position 8p21 (18). It is a relatively small
gene spanning 3.5 kb and composed of 6 exons, only the first
five being coding (19). The nucleotide sequence correspond-
ing to the mature peptide is restricted to exon 2. The pres-
ence of an alternative splice site in the beginning of exon 5
entails two distinct messenger species differing by the inser-
tion or deletion of 18 nucleotides. The possibility of the trans-
lation of the long (insertional) species has not been substan-
tiated to this day. The SFTPC gene expression is restricted to
the type II alveolar cells. The precursor (proSP-C), having a
MW of 22 kDa, is again subjected to a two-step proteolytic
processing yielding the 65-aa, 3.5-kDa, mature peptide. The
first step consists in the cleavage of the C-terminal domain,
yielding a 6-kDa intermediate peptide, and the second ends
with the cleavage of the N-terminal domain and yielding of
the mature peptide. Two cysteine residues present in the ma-
ture peptide are subjected to post-translational palmitoyla-
tion, which confers an extremely hydrophobic character to
the protein (20).
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surfactants, either artificial or natural (34, 35). It is es-
sential to prevent the development of HMD by balanc-
ing the indications for Caesarean sections, especially
basing the judgement on the qualitative or quantitative
analysis of the surfactant phospholipid material pre-
sent in amniotic fluid, which mirrors the fetal pul-
monary maturation, and by the injection of corticoids
to pregnant women 48 h before birth, especially when
the term is below 34 gestational weeks (33). Apart from
the two established risk factors of prematurity and low
birth weight, the male sex and the pathological condi-
tion of the mother (diabetes mellitus), factors such as
another case of HMD in siblings, as well as the Cau-
casian background, relate to possible maternal and/or
fetal genetic factors. Indeed, for an identical birth term,
two newborn babies will have distinct risks for HMD.
This fact is especially illustrated in dizygotic twin pairs,
which are by definition non-identical in terms of ge-
netic factors and are submitted to a unique environ-
ment. These dizygotic twin pairs, in contrast to
monozygotic twins, are as discordant with regard to
HMD as siblings adjusted for other risk factors would
be, and this discordance is likely to be due to genetic
factors (36). This not to mention term (a rare occur-
rence) or near-term-born babies who, despite the ab-
sence of established environmental risk factors, de-
velop HMD. Confirming these speculations, Floros and
co-workers observed linkage disequilibrium in infants
with neonatal respiratory distress syndrome as com-
pared to a control population using the compound in-
Fig. 5 Surfactant synthesis and turnover. The pulmonary
surfactant (phospholipids and proteins) is synthesized by the
type II alveolar cell and stored as lamellar bodies. Once ex-
creted, lamellar bodies give birth to tubular myelin, a highly
ordinated transitional lamellar structure precursor to the
monolayer. Surfactant is recycled or degraded by the type II
alveolar cell (90%) and the alveolar macrophage (10%).
Tab. 3 Genes whose products are involved in surfactant homeostasis.
Protein Gene Localization MIM1 Structure
SP-A SFTPA1 10q22.2–q23.1 178630 4 exons
SFTPA2 10q22–q23 178642 4 exons
SP-B SFTPB 2p12–p11.2 178640 11 exons
SP-C SFTPC 8p21 178620 6 exons
SP-D SFTPD 10q23.3 178635 7 exons
GM-CSF CSF2 5q31.1 138960 4 exons
GM-CSF receptor, α subunit CSF2RA Xp22.32/Yp11.3 306250 13 exons
(pseudo-autosomal region)
GM-CSF receptor, βc subunit CSF2RB 22q12.2–q13.1 138981 Introns-exons organization unknown
1 MIM: Mendelian Inheritance in Man entry number [see Online
Mendelian Inheritance in Man, OMIM™. McKusick-Nathans In-
stitute for Genetic Medicine, Johns Hopkins University (Balti-
more, MD) and National Center for Biotechnology Informa-
tion, National Library of Medicine (Bethesda, MD), 2000. World
Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/].
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sertion-deletion and (CA)n motif repeat polymorphism
of SFTPB intron 4 (37). These populations were
matched for gender, ethnic background and mean ges-
tational age. Since the variation lies in an intron, it may
be that slight changes in the expression of the gene,
and not deleterious mutations, confer susceptibility to
neonatal respiratory distress syndrome, especially
when established risk factors are present. Genetic vari-
ation within the genes encoding the SP-A protein
(SFTPA1 and SFTPA2 genes) also seems to correlate
with the risk for HMD since coding polymorphisms of
these genes show statistically significant differences in
allele sharing between cases and controls. Of interest
is that the odds ratios could differ significantly for a
given genotype between the African-American and
White Caucasian samples, suggesting that these poly-
morphisms were likely indirect disease markers rather
than causal genetic changes (38). In this study, a signif-
icant synergistic positive association was found be-
tween an SFTPA2 allele and the SFTPB intron 4 com-
pound polymorphism, suggesting the existence of an
interaction between the different polygenic risk factors.
More recently, specific genotypes at this locus (SFTPA1
6A2/6A2 and 6A3/6A3 genotypes) were shown to signifi-
cantly associate with high or low risk for HMD, respec-
tively, based on a case-control study performed in a ge-
netically homogeneous population sample from
Finland (39). Correlation with the SFTPB genotype
could not be tested because this population showed lit-
tle polymorphism at this locus. Recently, it was sug-
gested that the SFTPB T1580C (I131T) coding polymor-
phism was an upstream determinant for certain
SFTPA1/2 alleles causing genetic susceptibility to
RDS (6A2, 1A0) or protection against it (6A3, 1A2).
More specifically, allele assortment at the SFTPA1/2
locus was significantly different in RDS as compared
with controls only in a subgroup of subjects homo-
zygotes for a threonine in position 131 of the 
SP-B protein. This important paper sheds new light on
the causality of a common SP-B polymorphism in RDS,
and shows interaction with the SFTPA1/2 locus (87).
Interestingly, the SP-A protein in the mouse is en-
coded by a single gene and murine models with null
mutations at this locus were established. The Sftpa-/-
model is normally viable (24, 25) and lung function as
well as development are seemingly normal, despite
the observed scarcity of tubular myelin. Non-specific
abnormalities could be observed, such as delayed
clearance of certain bacteria from distal airway:
Pseudomonas aeruginosa and Streptococus group B,
which demonstrate the subtleness of the phenotype.
Obviously, these mice do not replicate the human dis-
ease HMD, or any other lung disease known in man.
This could be expected because no SFTPA1/2 deleteri-
ous mutations were observed in man, and since these
animal models are established as models for mono-
genic, not polygenic, disease. Whatever the case,
these knock-out animals provide a suitable tool for an-
alyzing the biological significance of the SP-A protein
in vivo.
Non-HMD abnormalities of surfactant synthesis or
turnover
A number of cases with respiratory distress not in-
cluded within the nosology of HMD are characterized
by a qualitative or quantitative abnormality of surfac-
tant. Among those which are inborn or so reputed, one
Tab. 4 Murine models.1
Gene knock-out mRNA Surfactant Phospholipids Tubular myelin Respiratory References
(human proteins phenotype
homologue)
Sftpa SFTPA: Absent SP-B, SP-C, Saturated Absent N (24, 25)
(SFTPA) SFTPB, SFTPC, SP-D: N phosphatidyl-
SFTPD: N cholines: ↑
Sftpb SFTPB: Absent SP-C: ↓↓↓ ND Absent Death due (26)
(SFTPB) SFTPA, SFTPC: N Aberrant/ to neonatal
immature respiratory
SP-C species distress
Sftpd SFTPD: Absent SP-A, SP-B: ↑ ↑ ND N (27)
(SFTPD) SFTPA, SFTPB, (giant lamellar
SFTPC: N bodies)
Sftpd SP-D: Absent SP-B, SP-C: N Saturated ↓ N (28)
(SFTPD) SFTPB, SFTPC: N SP-A: ↓ phosphatidyl-
SFTPA: ↓ (modest) (modest) cholines: ↑
Csfgm SFTPA, SFTPB, SP-A, SP-B: ↑ ↑ ↑ PAP (22, 29, 30)
(CSF2) SFTPC: N
Il3rbl ND ND ND ND PAP (23, 31)
(CSF2RB)
1 Mice homozygous for the mutation obtained through homol-
ogous recombination. The two Sftpd knock-out models were
treated separately. N: Normal; ND: Not determined; PAP: Pul-
monary alveolar proteinosis; ↑: Increase; ↓: Decrease; ↓↓↓:
Large decrease.
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can distinguish alveolar proteinosis, a heterogeneous
group from which a certain number of entities seem to
emerge. These disorders are being biochemically and
pathologically characterized, and their molecular bases
elucidated.
Alveolar proteinosis
Pulmonary alveolar proteinosis (PAP) is a rare res-
piratory disease, initially reported by Rosen and co-
workers some forty years ago (40). This condition is
generally idiopathic, although it has been described
as being associated to malignant hemopathies (leu-
kemias, lymphomas), or to lysinuric protein intoler-
ance, during or following respiratory infections
(nocardiosis, histoplasmosis, pneumocystosis, cyto-
megaloviral infections), and following exposure to in-
ert particles such as silica. The chest x-ray, performed
for respiratory distress, which is most often unex-
plained, shows alveolar opacities, as well as reactional
interstitial infiltrates (honeycombing). The pathologi-
cal examination of lung elicits periodic acid-Schiff
Fig. 6 Chest x-ray. This procedure carried out in a 5 month-
old infant suffering from severe alveolar proteinosis shows
nodular peri-hilar opacities in the context of diffuse interstitial
infiltrates.
Fig. 7 Chest computed tomography. This procedure, carried out in a 4 year-old child suffering from
alveolar proteinosis shows interstitial infiltrates and intra-alveolar filling.
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Fig. 8 Analysis of broncho-alveolar lavage fluid after PAS
staining (A) shows abundant lumpy proteinaceous material
(PAS, x 200) among the cells, whereas the standard staining at
higher magnification (B) shows enlarged macrophages laden
with lipid microvacuoles (foamy macrophages; MGG, x 400).
Fig. 9 Histological analysis of pulmonary biopsy sample fol-
lowing PAS staining highlights intra-alveolar filling with abun-
dant, lumpy, lipoproteinaceous, material containing small
cholesterol crystals, small chromaffin concretions and foamy
macrophages (PAS, x 100).
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(PAS)-positive, protein and lipid, material filling the
alveoli (41). PAP is diagnosed prevalently in the adult
but pediatric or neonatal forms are also seen (42, 43).
The pathology of these different forms is regarded as
being approximately identical.
PAP in the child and adult. Alveolar proteinosis can
be diagnosed at any age, from neonate (42) through to
maturity (72 years) (43), the age at the diagnosis being
most often between 20 and 50 (44). In the child and
adult, the revealing signs are, in more than half of the
cases, dyspnea and cough with progressive onset,
sometimes with cyanosis, finger clubbing, asthenia,
and weight loss. The PAP in children is polymorphic.
All intermediate forms are possible, from early neona-
tal forms (but with a symptom-free interval), evolving
towards uncontrollable respiratory insufficiency and
death, through non-symptomatic forms of fortuitous
diagnosis. The x-ray shows micronodular and/or scat-
tered reticulonodular opacities due to alveolar filling
(41) (Figures 6, 7). Spirometric data indicate moderate
restriction without obstruction. Standard biological
function tests do not contribute to diagnosis, except
an increase in plasma LDH, which is sometimes sharp,
but non-specific (45). Broncho-alveolar lavage (BAL)
is presently regarded as the reference diagnostic
method, recourse to surgical pulmonary biopsy being
more and more rare. BAL yields an opaque, milky fluid
suggestive of diagnosis. A PAS-positive material can
be found around, as well as inside, the macrophages
(Figure 8A). Macrophages are most often enlarged
and foamy (Figure 8B). Electron microscopy elicits
pseudo-myelin images made of onion bulb arrange-
ment of concentric lipid leaflets with dense bodies at a
center as well as fence-like structures corresponding
to tubular myelin. These abnormalities are the expres-
sion of the storage of both the protein and lipid frac-
tions of the surfactant. In adults, the study of BAL fluid
using immunohistochemistry may elicit an increased
amount of SP-A, SP-B (46) or SP-D (47). Assessment of
BAL lipids by thin-layer chromatography shows an in-
crease in phospholipids and a general profile quite
typical for pulmonary surfactant, although different
variants such as a decrease in phosphatidyglycerol or
an increase in sphingomyelins and in lysophos-
phatidylcholine may be observed (35). Unfortunately,
the pediatric data are presently inconsistent. The lung
biopsy, when performed, shows the storage of a gran-
ular PAS-positive, protein and lipid, material (Figure
9). The alveoli contain intensely eosinophilic bodies of
varied sizes, which represent the cellular debris
among which some foamy alveolar macrophages can
be seen.
Repeated broncho-alveolar lavage is today the only
treatment available for PAP, though makeshift, the dis-
ease course ranging from complete remission without
sequelae through to end-stage pulmonary fibrosis (48,
49).
Recently, the analysis of CSF2 gene-derived cDNAs
from an adult patient with PAP allowed the disclosure
of a heterozygous mutation accounting for an
isoleucine-threonine substitution, as compared to the
canonical sequence of human GM-CSF. In this individ-
ual, GM-CSF was not measurable after stimulation of
peripheral blood leukocytes and of cells retrieved from
broncho-alveolar lavage fluid (50). This case seems to
corroborate the present concept of altered surfactant
clearance, especially in the light of the knock-out
murine models (22, 29), and the therapeutic efficacy of
recombinant GM-CSF in some patients with PAP (51).
However, this isolated observation needs to be re-
garded as preliminary, because many questions, espe-
cially these regarding the actual patient’s genotype, re-
main unanswered.
Adding to the etiopathogenesis of this lung dis-
ease, the presence of blocking anti-GM-CSF antibod-
ies was demonstrated in the broncho-alveolar lavage
fluids and sera from patients with idiopathic (non-
congenital) PA P. These antibodies seem to be absent
in the established secondary forms of the disease, in
subjects with another type of lung disease and in
most healthy controls (52, 53).Thus, this observation
suggests a high diagnositic value for the presence of
anti-GM-CSF antibodies in patients with idiopathic,
but not secondary or congenital, PA P. Yet, it remains
to be determined whether the presence of anti-GM-
CSF antibodies is secondary or primary in these pa-
t i e n t s .
PAP in the neonate. The congenital form of alveolar
proteinosis (CAP) has its onset during the neonatal pe-
riod and its evolution is particularly severe. Prognosis
is very poor. This condition translates into neonatal
respiratory distress leading to death, which generally
occurs during the first year of life, despite maximal
medical care. Because precedents in the siblings are
not uncommon, and because several consanguineous
pedigrees were reported, it seems that the most com-
mon pattern of inheritance is autosomal recessive. If
one strictly adheres to the diagnostic criteria for alve-
olar proteinosis, i.e., the storage of both lipid and pro-
tein fractions of surfactant, the underlying molecular
defect(s) remain unknown, with a possible exception
discussed below. Again, this observation seems to
point at the GM-CSF (CSF2) signaling pathway (54)
and substantiate the original speculations regarding a
causal anomaly of surfactant homeostasis (55). In the
newborn child, the analysis of BAL fluid and pul-
monary biopsy samples were consistent with the di-
agnosis of PAP. Of note is that the SP-B protein was de-
tected. However, flow cytometry analysis showed a
marked deficiency in the β-chain common to the re-
ceptors for GM-CSF and interleukin-3 and interleukin-
5 (54). Only later, at the age of 20 months (the age at
which the patient became oxygen-dependent), was a
mutation of the corresponding gene (CSF2RB) demon-
strated. This mutation, a C→A transversion at nu-
cleotide 1835, was identified at the cDNA level. It ac-
counts for the substitution of a threonine for the
normal proline residue in position 602 (T602P). Unfor-
tunately, the genomic DNA from the patient and his
parents were not analyzed, and this throws doubt
upon the definitive validity of these data.
Murine models for alveolar proteinosis. The parallel
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between BAL profile and histological data from pa-
tients with alveolar proteinosis, and the murine mod-
els with an altered surfactant turnover, is impressive.
This concerns not only the Il3rb1-/- and Csfgm-/-, but
also the Sftpd-/- knock-outs (see Table 4 for more de-
tails). Indeed, two murine models whose phenotype
was originally unexpected add to the genetics of alve-
olar proteinosis. The equivalent of the human disease
is replicated by the ablation of the gene encoding the
β subunit of GM-CSF receptor (Il3rb1-/- mice) (23, 31),
or with the knock out of the gene encoding GMCSF it-
self (Csfgm-/- mice) (22, 29, 30). Indeed, these models
are characterized by an important storage of not only
protein, but also lipid within the lung. On the other
hand, ablation of murine Sftpd was obtained by two
research teams (27, 28) who published their results al-
most concomitantly. Sftpd-/- mice have altered pul-
monary surfactant homeostasis with progressive stor-
age of lipids, within lung tissue and alveolar space,
and develop emphysema (27, 28). At present, no dele-
terious mutations of the corresponding gene (SFTPD)
have been reported in any human lung disease. Based
on these murine models, CSF2, CSF2RB, and SFTPD
provide good candidates for genes mutated in human
alveolar proteinosis.
SP-B deficiency
Complete deficiency of the SP-B surfactant protein is a
constitutional disease with neonatal onset, accounting
for severe respiratory insufficiency, and was first re-
ported by Nogee and co-workers (56). The sponta-
neous evolution, based on the cases published to date,
is incompatible with prolonged life. This relatively un-
common genetic condition shows an autosomal reces-
sive pattern of inheritance. The authors of the seminal
paper on the subject reported the case of a child de-
ceased at the age of 5 months following neonatal res-
piratory distress. His condition was suggestive of alve-
olar proteinosis, with little or no effect of corticoids or
instillation of exogenous surfactants. Near fifty cases
of complete SP-B deficiency have been reported since
and diagnosis is now facilitated by the knowledge of
the molecular basis of the disease. The actual inci-
dence is unknown but seems very low, despite the like-
lihood that many cases remain undiagnosed (57). The
material present in the alveolar space is protein rich,
with no sign of storage of phospholipids. In this re-
spect, complete SP-B deficiency clearly differs from
CAP. The characterization of alveolar lavage fluid
shows not only the absence of the SP-B protein, but the
presence of incompletely or abnormally cleaved
species of the SP-C propeptide (proSP-C). These find-
ings suggest an important role for the SP-B protein in
subcellular trafficking and/or the proteolytic matura-
tion of the SP-C protein or its precursor (Figure 10) (58).
The singular observation of complete SP-B deficiency
associated with a thorough maturation of proSP-C in a
child heterozygous for two null mutations of the SFTPB
gene demonstrates that the absence of the SP-B pro-
tein, and not a defect in proSP-C processing, is the es-
sential cause of respiratory distress in these children
(59).
The ultrastructural study of pulmonary tissue by
electron microscopy shows interstitial fibrosis, hyper-
plasia of type II alveolar cells, desquamated epithelial
cells, and (protein) material filling the alveoli (56). The
absence of tubular myelin and the scarcity of lamellar
bodies are also characteristic for SP-B deficiency (60,
61). Analysis of lipid turnover in these children using
isotopes with an ingestion of [U-13C] glucose does not
Fig. 10 Quantitative analysis of pulmonary surfactant pro-
teins SP-B, SP-C, and of their precursors (proSP-B and proSP-
C) by immuno-TLC with use of anti-SP-B and anti-proSP-B
(lanes 1, 4), anti-SP-C and anti-proSP-C (lanes 2, 5) specific an-
tibodies in the patient (right) as compared to a healthy control
(left). The SP-B protein is undetectable in the patient who, in
addition, shows incompletely or abnormally processed
species of the proSP-C precursor, as compared to the control
who shows exclusively mature SP-B and SP-C. Lane 3, mo-
lecular weight (MW) marker with corresponding band values
indicated in kDa.
Fig. 11 121ins2 mutation of the SFTPB gene. The direct nu-
cleotide sequence from the (A) control (homozygous for the
wild-type allele) and from the (B) patient’s DNA (homozygous
for the mutated allele) shows that the 121ins2 mutation results
form the substitution of a GAA triplet (arrowhead, underlined)
to the second residue of a stretch of 5 cytosines (underlined).
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significantly depart from healthy controls, which sup-
ports that it is a near pure protein abnormality without
any consequences for lipid homeostasis, thereby con-
trasting with alveolar proteinosis (62). Finally, akin to
Tab. 5 Molecular pathology of the SFTPB gene.
R e f e r e n c e A l t e r n a t i v e M u t a t i o n M o l e c u l a r E x o n P a t i e n t SP-B protein C l i n i c a l R e f .
n o m e n c l a t u r ea d e s i g n a t i o nb t y p e s i g n i f i c a n c e g e n o t y p e p h e n o -
BAL or TA I m m u n o - t y p e
( E L I S A / h i s t o -
We s t e r n - c h e m i s t r y
b l o t ) ( a n t i - S P - B
l a b e l i n g )
T 5 2 C L 1 3 P S u b s t i t u t i o n M S 1 T 5 2 C / 1 5 4 9 C – – L e t h a l ( 6 6 )
→G A A
G 4 4 1 A W 3 9 X S u b s t i t u t i o n N S 2 G 4 4 1 A / 1 5 4 9 C N D – L e t h a l ( 6 6 )
→G A A
4 5 7 d e l C 4 5 d e l C Deletion F S 2 4 5 7 d e l C / 1 5 4 9 C – N D L e t h a l ( 5 9 )
→G A A
T 4 6 9 C C 4 9 R S u b s t i t u t i o n M S 2 T 4 6 9 C / 1 5 4 9 C – N D U n k n o w n ( 6 6 )
→G A A
G 5 0 4 A W 6 0 X S u b s t i t u t i o n N S 2 G 5 0 4 A / G 5 0 4 A – – L e t h a l ( 6 6 )
A 5 2 3 G I V S 2 + 4 A→G S u b s t i t u t i o n Exon skipping 2 A 5 2 3 G / A 5 2 3 G – – L e t h a l ( 6 6 )
( F S )
1 4 5 4 d e l A I V S 3 – 2 d e l A D e l e t i o n Exon skipping) 4 1 4 5 4 d e l A / 1 5 4 9 C N D – L e t h a l ( 6 6 )
( i n - f r a m e ) →G A A
T 1 4 8 6 G C 1 0 0 G S u b s t i t u t i o n M S 4 T 1 4 8 6 G / 1 5 4 9 C N D + (very U n k n o w n ( 6 6 )
→G A A r e d u c e d )
1 5 4 9 C→G A A 1 2 1 i n s 2 D e l e t i o n / F S 4 1 5 4 9 C→G A A / – – L e t h a l (60, 63–
i n s e r t i o n 1 5 4 9 C→G A A 65, 67)
1 5 5 2 d e l C 1 2 2 d e l C D e l e t i o n F S 4 1 5 5 2 d e l C / 1 5 4 9 C N D – L e t h a l ( 6 8 )
→G A A
1 5 5 3 d e l T 1 2 2 d e l T D e l e t i o n F S 4 1 5 5 3 d e l T / – – L e t h a l ( 6 9 )
1 5 5 3 d e l T
2 4 1 5 – 2 4 1 6 i n s A A 1 3 4 i n s 2 I n s e r t i o n F S 5 2 4 1 5 – 2 4 1 6 i n s A A / N D – L e t h a l ( 7 0 )
1 5 4 9 C→G A A
G 2 4 1 7 A G 1 3 5 S S u b s t i t u t i o n M S 5 G 2 4 1 7 A / ? – (D 38), then + (D 72) S u r v i v a l ( 7 1 )
+ (D 106)
G 2 4 7 9 T [ r. 4 7 9 g→u ; S u b s t i t u t i o n I s o s e m a n t i c 5 G 2 4 7 9 T / G 2 4 7 9 T N D + (very P r o l o n g e d ( 7 2 )
4 7 9 g→u mutation and/ r e d u c e d ) s u r v i v a l
+ 478_596del] or splicing
anomaly with
F S
G 2 9 1 3 A 2 2 4 G→A S u b s t i t u t i o n I s o s e m a n t i c 6 G 2 9 1 3 A / 1 5 4 9 C – N D L e t h a l ( 6 6 )
mutation and/ →G A A
or splicing
a n o m a l y
T 4 3 7 7 C C 2 3 5 R S u b s t i t u t i o n M S 7 T 4 3 7 7 C / 1 5 4 9 C – + (very L e t h a l ( 6 6 )
→G A A r e d u c e d )
C 4 3 8 0 T R 2 3 6 C S u b s t i t u t i o n N S 7 C 4 3 8 0 T / 1 5 4 9 C – + (very L e t h a l ( 7 3 )
→G A A r e d u c e d )
C 4 4 1 8 A C 2 4 8 X S u b s t i t u t i o n M S 7 C 4 4 1 8 A / 1 5 4 9 C – – Tr a n s p l a n - ( 6 6 )
→G A A t a t i o n
C 4 4 2 8 T R 2 5 2 C S u b s t i t u t i o n M S 7 C 4 4 2 8 T / C 4 4 2 8 T – + (very U n k n o w n ( 6 6 )
r e d u c e d )
6 1 0 9 – 6 1 1 0 i n s C C GT 3 4 3 – P 3 4 4 i n s PI n s e r t i o n Insertion of 9 6 1 0 9 i n s C C G / 6 1 0 9 i n s C C G – + (very L e t h a l ( 6 6 )
one amino acid r e d u c e d )
6 1 1 4 – 6 1 2 5 d e l G 3 4 5 – T 3 4 8 d e l D e l e t i o n Deletion of 9 6 1 1 4 – 6 1 2 5 d e l / – – L e t h a l ( 6 6 )
4 amino acids 1 5 4 9 C→G A A
a According to nucleotide position on the reference genomic
sequence (16), and the recommendations for a nomenclature
of human gene mutations (74). bAccording to codon number-
ing and/or consequences upon translation, or splicing. BAL:
broncho-alveolar lavage; D: day; FS: frameshift; MS: mis-
sense; NS: nonsense; ND: not determined; TA: tracheal aspi-
rate; –: negative; +: positive.
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show excess dead space (77). Briefly, these animals re-
semble the human disease, except for slight changes in
heterozygotes, and provide a suitable experimental
model for SP-B deficiency.
Diagnosing SP-B deficiency. Today, diagnosing SP-B
deficiency is feasible at the molecular level. Molecular
diagnosis is facilitated by the existence of a common
mutation (121ins2) which generates a restriction en-
donuclease cleavage site (Figure 12). Assessment of
this mutation must be performed in any term or near-
term born infant who shows signs of hyaline mem-
brane disease which do not evolve favourably after 5
days of life after a congenital pulmonary infection by
atypical micro-organisms (enteroviruses, mycoplas-
ma, chlamydia) and congenital heart disease have
been ruled out as a cause of hypoxemia or pulmonary
hypertension. This diagnostic strategy could be chal-
lenged since a number of distinct STFPB gene muta-
tions are now to be found in the literature. Such allelic
heterogeneity is in line with the general model of ge-
netic diseases proceeding through haplo-insufficiency.
These mutations are quite homogeneously scattered
throughout the gene, let alone the regulatory regions
(promotor region, 5’– and 3’UTR) (Table 5) and are
point mutations (including nonsense, mis-sense and
splice lesions) as well as short frameshift insertions or
deletions (66).
Milder forms of SP-B deficiency. Beside complete
SP-B protein deficiency, partial (66, 72, 73) or transient
(71) deficiencies have been reported. These deficien-
cies also lie in the framework of SFTPB. In particular,
several mutations underscoring partial deficiency were
reported, correlating with a complete absence of the
mature SP-B protein in tracheal aspirate, positive stain-
ing in type II alveolar cells for the intermediary 26-kDa
proSP-B species, and positive but faint staining for SP-
B within type II alveolar cells and the alveolar space.
This relates in particular to the T343-P344insP and mis-
sense C100G, C235R, R236C mutations, all of which re-
spect the reading frame (66, 73). More recently, a ho-
mozygous isosemantic mutation generating an
aberrant 3’ (acceptor) splice site competing with the
wild-type site (G2479T) (see Table 5) was observed in
two unrelated infants of the same ethnic background
(French Canadians) (72). This mutation accounts for a
decrease in mature SP-B synthesis and co-existence
with an aberrant protein. Although the disease is se-
vere and of neonatal onset, the associated phenotype
is not that of a 121ins2 mutation homozygote, since it is
compatible with prolonged survival. Analysis of pul-
monary tissue from one of the two infants who under-
went lung transplantation shows substantial decrease
of the SP-B protein (between 12 and 16% of normal
ranges).
Conclusions on SP-B deficiency. The molecular con-
sequences of SFTPB mutations can be found at any of
the steps of gene expression, such as absence of the
mature messenger (78), abnormality of transport/rout-
ing of the protein, abnormality of processing of the pre-
cursor species, or synthesis of a partially or completely
non-functional mature protein. Although the synthesis
congenital proteinosis, plasma LDH is extremely high,
reflecting the magnitude of damage to the respiratory
epithelium.
A frameshift mutation of the SFTPB gene (C→GAA,
codon 121), now commonly referred to as 121ins2, rep-
resents a non-negligible fraction of the molecular
pathology of the SFTPB gene in association with SP-B
deficiency (59, 60, 63–67) (see Table 5 for details re-
garding the molecular pathology of the SFTPB gene).
The prevalence of a given mutation could suggest the
existence of a founder effect, or a mutation hot spot
(Figure 11), although no obviously unstable nucleotide
structure seems to associate with this lesion of the
gene. The patients homozygous for the 121ins2 muta-
tion show a uniform disease course: severe respiratory
insufficiency with alveolar infiltrates on the x-ray in the
first hours of life, little or no improvement following ad-
ministration of exogenous surfactant or glucocorticoid,
and requirement for extracorporeal life support. Death
occurs during the first weeks or months of life, survival
being possible only at the cost of lung transplantation
(75). The 121ins2 heterozygotes have normal lung
function (76), in contrast to the knock-out murine mod-
els (77) (see below).
Murine model for SP-B deficiency. Among the two
genes encoding the hydrophobic proteins, only the
Sftpb gene has been knocked-out in mice to date (see
Table 4 for details). Homozygous (Sftpb-/-) mice die as
neonates due to severe respiratory distress (26). The
pathological characterization of their lungs shows the
complete absence of SP-B protein, and, as in man, the
presence of immature or abnormally processed SP-C
(proSP-C), and the absence of mature SP-C. Heterozy-
gotes have a defect in pulmonary compliance and
Fig. 12 Assessment of the 121ins2 mutation by PCR amplifi-
cation of exon 4 and endonuclease restriction using SfuI. This
figure shows the gel electrophoresis of the PCR products re-
stricted (odd lanes) and unrestricted (even lanes) from the fa-
ther (I-1; lanes 1, 2), the mother (I-2; lanes 3, 4), the proband (II-
1; lanes 5, 6), and the wild-type control (lanes 7, 8). The
corresponding band sizes are indicated in base pairs (bp).
From analysis of the electrophoretic pattern, the proband is
homozygous for the 121ins2 mutation which he has inherited
from his heterozygous parents.
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 14:17
Tredano et al.: Inborn errors of surfactant metabolism 103
of an abnormal mature SP-B protein without associ-
ated quantitative deficiency has not been shown in
man, transgenic murine models with proteins that are
deficient for the establishment of inter- or intra-chain
disulfide bonds, show the actual possibility of such a
phenomenon in man (79, 80).
Partial SP-B deficiencies can account for unusual
prolonged respiratory distress in the newborn child or
for a chronic intractable and apparently unexplained
lung disease in the toddler. The immunohistochemical
study of pulmonary tissue (lung biopsy) with labeling
of the surfactant proteins will then permit the diagno-
sis. In addition, these observations highlight the no-
tion of a threshold SP-B protein level compatible with
normal lung function (generation of tubular myelin,
proSP-C processing, surface tension of the monolayer,
etc.). Sftpb+/- heterozygous murine models, in which
one can observe gene dosage effect (Sftpb messenger
and corresponding protein levels decreased by half),
present with minor pulmonary function abnormalities
(see below) (77), whereas SFTPB 121ins2/wt heterozy-
gous humans have normal lung function (76). There-
fore, if there is a threshold SP-B protein level, this
threshold is expected to be different in man and mice,
and the difference probably resides in genetic loci that
are not allelic to SFTPB. This is clearly an opening to-
wards oligogenic, or multigenic inheritance. Indeed, it
is possible that individuals that are carriers of a muta-
tion reducing the production of SP-B protein are at risk
of developing lung disease, provided that an addi-
tional factor (mutation at another locus, secondary
disease) happens to alter SP-B protein metabolism.
Such a hypothesis was set forth as an explanation for
a transient complete SP-B deficiency in an individual
heterozygous for a mis-sense mutation (G135S, exon
5), inherited from the healthy mother, without any se-
quence deviation identified on the paternal allele (71).
Other abnormalities of surfactant
Recently, a term-born child with an apparently unex-
plained neonatal respiratory distress was reported,
which did not meet the diagnostic criteria for either
alveolar proteinosis or SP-B deficiency. In this child,
transmission electron microscopy showed a defi-
ciency in lamellar bodies within type II alveolar cells
(81). Although this observation is clearly a precedent,
it mirrors the observed heterogeneity in the protein
profiles in children (familial and sporadic cases) with
respiratory distress which led to the exploration of a
possible primary abnormality of pulmonary surfac-
tant, and one might speculate that a large number of
nosologically distinct entities remain to be identified.
Strategy for Ascertainment of Infants with Suspected
Abnormalities of Surfactant
The molecular basis of alveolar proteinosis in man re-
mains to be elucidated. Practically, the children show-
ing primary or unexplained respiratory distress possi-
bly consistent with alveolar proteinosis or SP-B defi-
ciency are justifiable of the same diagnostic chart.
Based on the prevalence of a particular mutation of the
SFTPB gene (1549C→GAA, or 121ins2 mutation) in this
group of patients, it seems completely justified to as-
sess its presence in all term-born children with unex-
plained respiratory distress using molecular screening
(Figure 12), even prior to the completion of the bio-
chemical analysis of surfactant. Indeed, this mutation
generates a recognition site for restriction endonucle-
ases (SfuI, TaqI). Assessment of this mutation must be
carried out in emergency, owing to the extremely se-
vere phenotype entailed by complete SP-B deficiency,
and because of the very short time interval for a possi-
Fig. 13 Segregation analysis of SFTPB locus markers in two
potentially informative families. The filled symbols designate
effected individuals. Alleles at loci D2S1331, D2S388,
D2S2232 (82) and the T1580C substitution polymorphism (83)
are indicated from the telomere towards the centromere, from
top to bottom. The haplotypes were set up based on the least
number of recombination events. Family 1: the presence of
two distinct haplotypes in the proband of this consan-
guineous pedigree constitutes a near-formal exclusion of the
locus, considering the rarity of SP-B deficiency. Family 2: the
presence of two non-haploidentical affected subjects, and ev-
idence of common haplotypes shared by both an affected in-
dividual (I-1) and his healthy sisters (II-2, II-3) again allow ex-
clusion of the SFTPB locus.
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 14:17
104 Tredano et al.: Inborn errors of surfactant metabolism
ble pulmonary graft. The segregation analysis of poly-
morphic DNA markers can occasionally prove very
useful when formal exclusion of the SFTPB locus al-
lows to spare the tedious molecular sequencing of the
11 exons and promotor region of the gene. Such segre-
gation analyses can be carried out in potentially infor-
mative families such as consanguineous pedigrees, or
if there exists an affected sibling with an available
source of DNA (Figure 13). Although assessment for
the 121ins2 mutation is justified outright, this diagnos-
tic test should not hinder a detailed biochemical char-
acterization of surfactant before the molecular study is
resumed. Such biochemical characterization is ideally
carried out from broncho-alveolar lavage fluid and con-
sists of the assessment of the four surfactant proteins
using ELISA (SP-B, SP-D, SP-A) and immuno-thin-layer
chromatography, SDS-PAGE or Western blotting (SP-B,
SP-C), with aid of antibodies (Figure 10). In addition,
the native and/or aberrant species of SP-C are to be
identified using an anti-proSP-C antibody, notably in
the case of an SP-B deficiency. This analysis should be
performed as distantly as possible from any instillation
of exogenous surfactant. The recent demonstration of
SP-B and SP-C assessment using high-performance
liquid chromatography (HPLC) might rapidly expand
this fast-moving field of specialized clinical chemistry
(84). Pulmonary biopsy followed by immunohisto-
chemistry is less and less justified, although still infor-
mative, especially in the cases with partial SP-B defi-
ciency, or when there are technical artefacts due to the
presence of cell debris in broncho-alveolar lavage fluid.
So far, only two or three specialized laboratories in the
world are of the right calibre to complete this kind of
study. At this point, there are no consensus diagnostic
guide-lines. The molecular exploration of protein defi-
ciencies other than SP-B's are exclusively research pro-
tocols, because no mutation of the SFTPC, SFTPD,
SFTPA1/2 genes has been shown in man. In the ab-
sence of a well characterized surfactant protein defi-
ciency, the protein can be present although abnormal,
and could be recognized by the antibodies. On the con-
trary, absence of a clear protein deficiency can be con-
sistent with a primary abnormality of surfactant metab-
olism. Each laboratory will have guide-lines according
to the specialized techniques they handle best. Accord-
ing to some authors, the GM-CSF signaling pathway
can be explored, e.g., with the quantitation of the α and
β subunits of GM-CSF receptor using flow cytometry
(54, 85). The assessment of GM-CSF’s affinity for its re-
ceptor can be performed using binding studies (54),
and the CSF2, CSF2RA, and CSF2RB messengers can
be analyzed for a mutation (86). This ascertainment
strategy is shown in Figure 14 and details concerning
the biological samples appear in Table 6.
Fig. 14 General scheme for diagnostic ascertainment of a
child showing unexplained respiratory distress with suspi-
cion of a primitive abnormality of pulmonary surfactant. The
simultaneous analysis of DNA, screening for the 121ins2 mu-
tation, and of bronchoalveolar lavage (BAL) fluid or tracheal
aspirate (TA) for the SP-B protein and precursor protein
proSP-C constitute the first step. The diagnosis of SP-B defi-
ciency is above all biochemical (absence or traces of SP-B
protein, aberrant and/or immature SP-C/proSP-C species),
and it will be corroborated by evidence for a homozygous
(especially 121ins2/121ins2) or compoundly heterozygous
SFTPB gene mutation. Assessment of a possible deficiency in
another surfactant protein, or of a possible primitive abnor-
mality of surfactant metabolism at large (GM-CSF pathway)
needs specialized research laboratory. The place of pul-
monary biopsy, non rarely carried out, remains to be deter-
mined (post mortem diagnosis, BAL analysis impossible or
inconclusive, abnormality of SP-B excretion, analysis of gene
messengers).
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Conclusion
Beside hyaline membrane disease of the preterm
neonate, discrete nosologic entities accounting for a
number of cases of respiratory distress in the neonate,
child or adult are currently being identified. Alveolar
proteinosis, the genetic basis of which remains to be
determined, is a heterogeneous disease cluster from
which surfactant protein B deficiency has been clearly
singled out. This is presently regarded as a distinct
primitive abnormality of surfactant metabolism, due to
the absence of lipid storage within the alveoli. The al-
lelic heterogeneity observed so far could be consistent
with a heterogeneity in both the clinical translation and
biochemical or pathological findings. The bulk of data
presently available suggest substantial complexity of
surfactant metabolism, especially regarding the rela-
tionship between SP-B protein and phospholipids, and
SP-B's involvement in the generation of a thoroughly
processed SP-C protein. As for the GM-CSF signaling
pathway, the diagnostic value of anti-GM-CSF antibod-
ies and the knock-out murine models indicate a more-
than-anecdotal involvement. However, the specific
pathophysiological mechanisms involving GM-CSF in
human disease remain obscure. Whatever the case, the
research into this cytokine seems promising because of
the possible therapeutic consequences such as replace-
ment therapy and bone marrow transplantation.
Analysis of genes involved in the pulmonary surfac-
tant metabolism opens a number of new perspectives
in terms of etiological diagnosis and the specific care
such as differentiated treatment or genetic counseling.
In addition, these genes, based on polymorphisms and
other minor alterations, may also affect the clinical
course of genetically and/or environmentally deter-
mined conditions where surfactant abnormalities were
noted (asthma, cystic fibrosis, etc.) and thus act as mod-
ifying genes. Conversely, they might confer a certain
risk for discrete lung diseases such as HMD and thereby
act as susceptibility genes. Population genetics and the
study of population isolates will hopefully bring some
of the genes to light. Much remains to be done and only
an integrated clinical biological approach will enable
satisfactory answers to our questions on the etiopatho-
genesis of this novel cluster of lung diseases.
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